Greater levels of a disintegrin and metalloproteinase with thrombospondin motifs 9 (ADAMTS-9) were found to be associated with greater risk for major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI), according to a study published in Angiology.

Researchers assessed the level of ADAMTS-9 in 666 patients (without coronary artery disease [CAD]: n=214; mean age, 57.1 ± 14.3 years; 55.1% men; with CAD: n=452; mean age, 60.0 ± 11.4 years; 75.2% men) who underwent coronary angiography. Patients with CAD were divided into those with stable angina pectoris (SAP), unstable angina, non–ST-segment elevation myocardial infarction (NSTEMI), or STEMI.

All participants were continuously followed up until the first major adverse cardiovascular event (MACE), for up to 2 years (mean, 12 months; interquartile range, 12 months). There was a greater prevalence of hypertension, diabetes, and smoking and lower use of antidiabetic drugs in patients with vs without CAD.

Serum level of ADAMTS-9 was higher in patients with vs without CAD (37.53 ± 8.55 ng/mL vs 12.04 ± 7.02 ng/mL, respectively; P <.001) and was found to be an independent predictor of CAD (odds ratio, 1.871; 95% CI, 1.533-2.283; P <.001). Among patients CAD, those with acute coronary syndrome (ACS) had higher serum levels of ADAMTS-9 compared with patients with SAP.

ADAMTS-9 levels were found to be correlated with the SYNTAX score (r = 0.523; P <.001). Patients with AMI and increased vs lower levels of ADAMTS-9 had a higher risk for MACE within 12 months (log-rank = 4.490; P =.034).

Coronary Artery Disease Severity and Levels of ADAMTS-9

Want to read more?

Want to read more?